Alnylam Pharmaceuticals Inc (ALNY)

143.39 +6.02  +4.38% NASDAQ Mar 5, 20:00 USD
View Full Chart
Price Chart
View All ALNY News

News

View All Events

Events

Date Type Description
05/06/2021 Earnings Alnylam Pharmaceuticals Inc First Quarter Earnings Results for 2021
05/06/2021 Misc Alnylam Pharmaceuticals Inc First Quarter Earnings Conference Call for 2021
02/11/2021 Earnings Alnylam Pharmaceuticals Inc Fourth Quarter Earnings Result for 2020
02/11/2021 08:30 EST Misc Alnylam Pharmaceuticals Inc Fourth Quarter Earnings Conference Call for 2020
02/11/2021 Misc Alnylam Pharmaceuticals Inc Annual Report for 2020
11/05/2020 Earnings Alnylam Pharmaceuticals Inc Third Quarter Earnings Result for 2020
11/05/2020 08:30 EST Misc Alnylam Pharmaceuticals Inc Third Quarter Earnings Conference Call for 2020
08/06/2020 Earnings Alnylam Pharmaceuticals Inc Second Quarter Earnings Result for 2020
08/06/2020 08:30 EDT Misc Alnylam Pharmaceuticals Inc Second Quarter Earnings Conference Call for 2020
05/06/2020 12:00 EDT Misc Alnylam Pharmaceuticals Inc Annual General Meeting for 2019
View All Performance Charts

Total Returns Comparison

Ratings & Reports

Advertisement
Edit

Profile

  • URL: https://www.alnylam.com
  • Investor Relations URL: http://investors.alnylam.com/index.cfm
  • HQ State/Province: Massachusetts
  • Sector: Healthcare
  • Industry: Biotechnology
  • Equity Style: Mid Cap/Growth
  • Next Earnings Release: May. 06, 2021
  • Last Earnings Release: Feb. 11, 2021
  • Next Ex-Dividend Date: N/A
  • Last Ex-Dividend Date: N/A
  • Description: Alnylam Pharmaceuticals Inc is a leader in the study of RNA interference and is attempting to harness this mechanism to create a new class of drugs. In addition to FDA-approved patisiran (Onpattro) for amyloidosis and givosiran (Givlaari) for acute hepatic porphyria, Alnylam has several partnered several pipeline candidates in rare genetic diseases, liver diseases, and other indications as well. Up-front fees from research partnerships with firms such as Regeneron, Sanofi, and The Medicines Company have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

Top Fund Holders

Symbol Name Weighting
FIJYX Fidelity Advisor® Biotechnology Z 5.22%
FBT First Trust NYSE Arca Biotech ETF 3.12%
BBH VanEck Vectors Biotech ETF 3.07%
FBIOX Fidelity® Select Biotechnology 2.44%
VGHCX Vanguard Health Care Inv 2.16%
HQL Tekla Life Sciences Investors 2.06%
IBB iShares Nasdaq Biotechnology ETF 1.39%
FSPHX Fidelity® Select Health Care 1.33%
HQH Tekla Healthcare Investors 1.22%
XBI SPDR® S&P Biotech ETF 1.00%
FGCKX Fidelity® Growth Company K 0.84%
FCGSX Fidelity® Series Growth Company 0.80%

Comparables

Edit
Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.


Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.